Kanaya Kohei, Tsuchida Yoshihiko, Inobe Manabu, Murakami Masaaki, Hirose Toshiaki, Kon Shigeyuki, Kawaguchi Satoshi, Wada Takuro, Yamashita Toshihiko, Ishii Seiichi, Uede Toshimitsu
Division of Molecular Immunology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.
Transplantation. 2003 Feb 15;75(3):275-81. doi: 10.1097/01.TP.0000046966.35399.75.
The blockade of costimulatory signal pathway by anti-CD40 ligand antibody or cytotoxic T lymphocyte antigen 4 immunoglobulin (CTLA4Ig) prolongs allograft survival in various vascularized organ transplantations. Because of the short half life of these agents, repeated administration of proteins is required to achieve significant graft survival. Furthermore, there is limited information regarding the effect of cosimulatory blockade on the survival of composite tissue allografts. Therefore, we examined the effect of adenovirus-mediated gene transfer of CTLA4Ig or CD40Ig gene or both in composite tissue allotransplantation.
The hind limbs removed from male ACI rats (RT1 ) were transplanted into female Lewis rats (RT1 ) heterotopically. The recombinant adenovirus carrying CTLA4Ig (AxCTLA4Ig) or CD40Ig (AxCD40Ig) was intravenously administered after limb transplantation.
Limb allograft survival was significantly prolonged by either AxCTLA4Ig or AxCD40Ig treatment at 1 x 10 plaque forming unit (mean survival time [MST] of 39.4+/-6.0 and 13.0+/-2.9, respectively) compared with the adenovirus vector containing beta-galactosidase-treated group (MST of 4.8+/-0.8). Combination of AxCTLA4Ig and AxCD40Ig led to significant prolongation of graft survival (MST of 49.2+/-6.6). Serum levels of CD40Ig were higher in rats treated with combination therapy than those treated with AxCD40Ig alone, whereas the serum levels of CTLA4Ig in rats treated with AxCTLA4Ig alone and AxCTLA4Ig and AxCD40Ig combined were very similar.
This study indicates that an adenovirus-mediated gene therapy of CTLA4Ig or CD40Ig has a therapeutic potential for preventing rejection in composite tissue transplantation. Furthermore, a combination therapy of AxCTLA4Ig and AxCD40Ig was even more effective in preventing acute rejection and prolonging the survival of allografted limbs without apparent complication.
抗CD40配体抗体或细胞毒性T淋巴细胞相关抗原4免疫球蛋白(CTLA4Ig)阻断共刺激信号通路可延长多种血管化器官移植中同种异体移植物的存活时间。由于这些药物半衰期短,需要重复给药蛋白质才能显著延长移植物存活时间。此外,关于共刺激阻断对复合组织同种异体移植物存活的影响,相关信息有限。因此,我们研究了腺病毒介导的CTLA4Ig或CD40Ig基因或两者基因转移在复合组织同种异体移植中的作用。
将雄性ACI大鼠(RT1)的后肢异位移植到雌性Lewis大鼠(RT1)体内。肢体移植后静脉注射携带CTLA4Ig(AxCTLA4Ig)或CD40Ig(AxCD40Ig)的重组腺病毒。
与含β-半乳糖苷酶的腺病毒载体处理组(平均存活时间[MST]为4.8±0.8)相比,AxCTLA4Ig或AxCD40Ig处理(剂量为1×10噬斑形成单位)均显著延长了肢体同种异体移植物的存活时间(MST分别为39.4±6.0和13.0±2.9)。AxCTLA4Ig和AxCD40Ig联合使用导致移植物存活时间显著延长(MST为49.2±6.6)。联合治疗组大鼠血清中CD40Ig水平高于单独使用AxCD40Ig治疗组,而单独使用AxCTLA4Ig治疗组以及AxCTLA4Ig和AxCD40Ig联合治疗组大鼠血清中CTLA4Ig水平非常相似。
本研究表明,腺病毒介导的CTLA4Ig或CD40Ig基因治疗在预防复合组织移植排斥反应方面具有治疗潜力。此外,AxCTLA4Ig和AxCD40Ig联合治疗在预防急性排斥反应和延长同种异体移植肢体存活时间方面更有效,且无明显并发症。